Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several ...

A novel immuno-PET/CT imaging technique has identified and validated a potent biomarker for nasopharyngeal cancer (NPC). The biomarker, CD70, is highly and constantly expressed in NPCs, and ...

The randomized, phase 3 study is enrolling patients with metastatic kidney cancer who are initially treated with an ...

Additionally, infiltrative RCCs were all clear ... renal tumors, previously published studies mostly focused on identifying benign and malignant renal lesions or distinguishing different types of RCCs ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Michael Hofman presented an in-depth ...

Patients with lymphovascular invasion are at increased risk for renal ... year cancer-specific survival rate of 59% vs 90%, respectively, in patients with papillary disease. In the clear cell ...

that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib. Results from ...

The most common primary tumor metastizing to the thyroid on autopsy is lung cancer, but, in clinically detected thyroid metastases, clear cell renal cell carcinoma (ccRCC) is the most frequent primary ...